Navigation Links
UC Davis bench-to-bedside research: Promising treatment in clinical trials
Date:3/26/2009

properties of the s-EH inhibitors to the stage where we could present a convincing picture to venture groups of compounds ready to move to the clinic."

In 2005, the company raised more than $51 million in Series A financing led by Frazier Healthcare Ventures, Alta Partners, Three Arch Partners, Burrill & Company and Altitude Life Science Ventures.

Today, the biotech company, based in Hayward, is dedicated to the discovery and development of novel drugs to treat type 2 diabetes, hypertension and inflammatory disorders, Hammock said. It is billed as the "world's leading company focused on s-EH, an important enzyme for the metabolism of arachidonic acid that plays an essential role in metabolic, inflammatory and cardiovascular physiology."

"Our main goal," Hammock said, "was to set up a system of a science-driven company where we reduce the cost of drug registration by using very good incisive science. We also want to reward and motivate the people who do the work; provide a funding and training environment to help teach students and postgraduates to write proposals; and allow scientists to move between an academic and industrial environment in the early stage to help determine career directions."

Another goal: a low-cost, affordable drug. "The sickest people in the world, of course, cannot pay for the drugs they need," Hammock said. "The chemistry developed around the s-EH inhibitors allows us to make powerful but inexpensive drugs that could be produced in developing countries."

Meanwhile, the clinical trials under way represent two firsts, said James Sabry, president and chief executive officer of Arte Therapeutics. "This is the first clinical study of a s-EH inhibitor in patients, and the first study designed to establish proof of concept that s-EH inhibition modulates glucose metabolism or blood pressure in patients with impaired glucose tolerance and hypertension."

."AR9281 has demonstrated an excellent
'/>"/>

Contact: Kathy Keatley Garvey
kegarvey@ucdavis.edu
530-754-6894
University of California - Davis
Source:Eurekalert  

Page: 1 2 3 4 5

Related biology news :

1. UC Davis research shows that newly discovered drug reduces heart enlargement
2. UC Davis researchers find molecule that targets brain tumors
3. UC Davis discovery offers hope for treating kidney cancer
4. UC Davis team refines cancer treatments to reduce potential nerve damage
5. UC Davis researchers exploring gene therapy to fight AIDS
6. UC Davis researchers discover Achilles heel in pancreatic cancer
7. UC Davis researchers discover a key to aggressive breast cancer
8. UC Davis chemical ecologist wins major award
9. UC Davis researchers discover new drug target for inflammatory disease
10. UC Davis researchers define characteristics, treatment options for XXYY syndrome
11. UC Davis researcher leads climate-change discovery
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
UC Davis bench-to-bedside research: Promising treatment in clinical trials
(Date:7/21/2015)... Today, ZTE announced its Android smartphone Axon, ... expected revenues in 2015 that relate to sales of FPC1025 for ... approximately 2,200 MSEK for 2015. Jörgen Lantto, CEO of ... in China and we are proud that ... for Axon , its first ...
(Date:7/21/2015)... 2015 Passwords have proven futile for ... recent U.S. Office of Personnel Management breach. Biometric ... conundrum, but developers and end-users are concerned about ... dilemma, Biometrics-as-a-Service provider HYPR Corp. announced today the ... third party integration. A video ...
(Date:7/13/2015)... , July 13, 2015 Synaptics Inc. ... human interface solutions, today announced sampling of ClearPad ... display driver integration (TDDI) product targeting smartphones and ... to combine Synaptics , best-in-class touch controller ... driver technology developed in the company,s Japan Design ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3
... Earth,s paleoclimate history by NASA,s Goddard Institute for Space ... rapid climate changes this century, including multiple meters of ... By looking at how the Earth,s climate responded ... fundamental question raised by ongoing human-caused climate change: "What ...
... of bees and brains made up of neurons make decisions ... Dec. 9 issue of Science . In previous ... in a honeybee swarm perform "waggle dances" to prompt other ... found. In the new study, Seeley, a professor ...
... economy (HE), in which hydrogen would replace the carbon-based fossil ... 1970s. Today, HE is seen as a potential solution to ... reserves. A research paper to be published in the ... wrong and SHE has the answer in the sustainable hydrogen ...
Cached Biology News:Paleoclimate record points toward potential rapid climate changes 2Paleoclimate record points toward potential rapid climate changes 3Paleoclimate record points toward potential rapid climate changes 4Building a sustainable hydrogen economy 2
(Date:7/29/2015)... ... July 29, 2015 , ... Brady (NYSE:BRC), a global ... Guide . To align chemical container labeling with OSHA’s updated Hazard Communication (HazCom) ... components, an example of an accurate label, and pictogram uses and meanings. , ...
(Date:7/29/2015)...  Indivior PLC (LON: INDV) today announced that the ... accepted and received Priority Review by the U.S. Food ... overdose. This naloxone nasal spray comes as a pre-filled ... into the nasal mucosa. 1 The device has ... be better equipped to help an opioid overdose victim. ...
(Date:7/29/2015)... ... July 29, 2015 , ... Finding gooey or crusty material in the ... there are a considerable number of terms in popular use to describe it, ophthalmologists ... a mixture of mucus, blood cells, skin cells and dust, but until now there ...
(Date:7/29/2015)... ... July 29, 2015 , ... Rainbow Scientific, Inc. (RSI), ... the availability of BI’s line of human mesenchymal stem cell (hMSC) differentiation media, ... media offer a complete system for multipotency evaluation of hMSCs and reliable induction ...
Breaking Biology Technology:Brady Announces a New GHS Label Guide 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 3Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 4Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 5What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 2What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 3What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 4Rainbow Scientific, Inc. Announces Availability of Human Mesenchymal Stem Cell Differentiation Media 2Rainbow Scientific, Inc. Announces Availability of Human Mesenchymal Stem Cell Differentiation Media 3
... May 5, 2011 Advanced Life Sciences Holdings, ... the discovery, development and commercialization of novel drugs in ... announced today that it has suspended operations and terminated ...   (Logo:   http://photos.prnewswire.com/prnh/20080218/ALSLOGO ) ...
... Codexis, Inc. (NASDAQ: CDXS ) today announced ...   First Quarter Financial Highlights:Revenue: For the ... million, an increase of 21% from $25.7 million in the ... 106% over the same time period driven by more than ...
... CARLOS, Calif., May 5, 2011 PharmacoFore, Inc., a ... announced today that it is a sponsor of the ... Meeting, scheduled for November 29, 2011 in Washington, DC. ... CEO of PharmacoFore, Inc., stated, "PharmacoFore shares CLAAD,s objective ...
Cached Biology Technology:Advanced Life Sciences Suspends Operations 2Codexis Reports First Quarter 2011 Results 2Codexis Reports First Quarter 2011 Results 3Codexis Reports First Quarter 2011 Results 4Codexis Reports First Quarter 2011 Results 5Codexis Reports First Quarter 2011 Results 6Codexis Reports First Quarter 2011 Results 7PharmacoFore, Inc. Announces Sponsorship of the 2011 CLAAD National Prescription Drug Abuse Prevention Policy Consensus Meeting on November 29, 2011 in Washington, DC 2PharmacoFore, Inc. Announces Sponsorship of the 2011 CLAAD National Prescription Drug Abuse Prevention Policy Consensus Meeting on November 29, 2011 in Washington, DC 3
Mycoplasma tested...
RayBio L Series 507: RayBio Label-based Antibody Array I (1 glass slide with 2 subarrays) Class: Antibody Array Products Product Group: Antibody Array...
...
Request Info...
Biology Products: